{"transactions":[{"id":882563,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-25T16:57:39.000Z","date":"2026-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4475},"source":{"system":"sec-edgar","filing":"0001005544-26-000004","document":"wk-form4_1772056655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000100554426000004/wk-form4_1772056655.xml","form_type":"4"}},{"id":882562,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T16:57:39.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":4475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":124119,"source":{"system":"sec-edgar","filing":"0001005544-26-000004","document":"wk-form4_1772056655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000100554426000004/wk-form4_1772056655.xml","form_type":"4"}},{"id":891552,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-02-20T16:40:32.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":4977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option vests on February 18, 2027."}],"balance_after":4977,"derivative":{"exercise_price":50.2,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":4977},"source":{"system":"sec-edgar","filing":"0001005544-26-000002","document":"wk-form4_1771623627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000100554426000002/wk-form4_1771623627.xml","form_type":"4"}},{"id":891551,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-20T16:40:32.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":2989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027."}],"balance_after":2989,"derivative":{"underlying":"Common Stock","underlying_shares":2989},"source":{"system":"sec-edgar","filing":"0001005544-26-000002","document":"wk-form4_1771623627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000100554426000002/wk-form4_1771623627.xml","form_type":"4"}},{"id":990579,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-11-24T18:16:53.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":12.98,"exercise_date":"2017-03-01","expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-25-053877","document":"wk-form4_1764026210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025053877/wk-form4_1764026210.xml","form_type":"4"}},{"id":990578,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T18:16:53.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":12.98,"value":194700.0,"ownership":{"direct":true},"balance_after":119644,"source":{"system":"sec-edgar","filing":"0001628280-25-053877","document":"wk-form4_1764026210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025053877/wk-form4_1764026210.xml","form_type":"4"}},{"id":1020522,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T16:21:00.000Z","date":"2025-10-09","kind":"sale","planned":true,"acquired":false,"shares":1200,"price":51.55,"value":61860.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.39 to $51.76. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":104644,"source":{"system":"sec-edgar","filing":"0001628280-25-044797","document":"wk-form4_1760127657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025044797/wk-form4_1760127657.xml","form_type":"4"}},{"id":1020521,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T16:21:00.000Z","date":"2025-10-09","kind":"sale","planned":true,"acquired":false,"shares":23800,"price":50.73,"value":1207374.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.12 to $51.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":105844,"source":{"system":"sec-edgar","filing":"0001628280-25-044797","document":"wk-form4_1760127657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025044797/wk-form4_1760127657.xml","form_type":"4"}},{"id":1053145,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-29T16:05:08.000Z","date":"2025-08-27","kind":"sale","planned":true,"acquired":false,"shares":3588,"price":45.01,"value":161495.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.04. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":129644,"source":{"system":"sec-edgar","filing":"0001005544-25-000008","document":"wk-form4_1756497902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000100554425000008/wk-form4_1756497902.xml","form_type":"4"}},{"id":1054865,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-27T16:56:58.000Z","date":"2025-08-25","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":45,"value":45000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":133232,"source":{"system":"sec-edgar","filing":"0001005544-25-000006","document":"wk-form4_1756328215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000100554425000006/wk-form4_1756328215.xml","form_type":"4"}},{"id":1056117,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T16:19:57.000Z","date":"2025-08-22","kind":"sale","planned":true,"acquired":false,"shares":1412,"price":45,"value":63540.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":134232,"source":{"system":"sec-edgar","filing":"0001005544-25-000004","document":"wk-form4_1756239595.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000100554425000004/wk-form4_1756239595.xml","form_type":"4"}},{"id":1250729,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-02-24T17:47:26.000Z","date":"2025-02-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5369},"source":{"system":"sec-edgar","filing":"0001628280-25-007476","document":"wk-form4_1740437240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025007476/wk-form4_1740437240.xml","form_type":"4"}},{"id":1250728,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-24T17:47:26.000Z","date":"2025-02-22","kind":"grant","planned":false,"acquired":true,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":135644,"source":{"system":"sec-edgar","filing":"0001628280-25-007476","document":"wk-form4_1740437240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025007476/wk-form4_1740437240.xml","form_type":"4"}},{"id":1254038,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-02-21T16:50:48.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":4475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026."}],"balance_after":4475,"derivative":{"underlying":"Common Stock","underlying_shares":4475},"source":{"system":"sec-edgar","filing":"0001628280-25-007189","document":"wk-form4_1740174641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025007189/wk-form4_1740174641.xml","form_type":"4"}},{"id":1254037,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-02-21T16:50:48.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":7296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on February 19, 2026."}],"balance_after":7296,"derivative":{"exercise_price":33.52,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":7296},"source":{"system":"sec-edgar","filing":"0001628280-25-007189","document":"wk-form4_1740174641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828025007189/wk-form4_1740174641.xml","form_type":"4"}},{"id":1369761,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-11-12T16:15:18.000Z","date":"2024-11-11","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":9.13,"exercise_date":"2016-03-03","expiration_date":"2025-03-03","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-047155","document":"wk-form4_1731446109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828024047155/wk-form4_1731446109.xml","form_type":"4"}},{"id":1369760,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-12T16:15:18.000Z","date":"2024-11-11","kind":"sale","planned":false,"acquired":false,"shares":10700,"price":36.24,"value":387768.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $36.46. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":130275,"source":{"system":"sec-edgar","filing":"0001628280-24-047155","document":"wk-form4_1731446109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828024047155/wk-form4_1731446109.xml","form_type":"4"}},{"id":1369759,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-12T16:15:18.000Z","date":"2024-11-11","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":9.13,"value":182600.0,"ownership":{"direct":true},"balance_after":140975,"source":{"system":"sec-edgar","filing":"0001628280-24-047155","document":"wk-form4_1731446109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000162828024047155/wk-form4_1731446109.xml","form_type":"4"}},{"id":1616961,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-27T17:04:34.000Z","date":"2024-02-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3886},"source":{"system":"sec-edgar","filing":"0001104659-24-028281","document":"tm247055-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465924028281/tm247055-15_4seq1.xml","form_type":"4"}},{"id":1616960,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T17:04:34.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":3886,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":120975,"source":{"system":"sec-edgar","filing":"0001104659-24-028281","document":"tm247055-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465924028281/tm247055-15_4seq1.xml","form_type":"4"}},{"id":1620438,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-02-26T17:02:36.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025."}],"balance_after":5369,"derivative":{"underlying":"Common Stock","underlying_shares":5369},"source":{"system":"sec-edgar","filing":"0001104659-24-027579","document":"tm247055-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465924027579/tm247055-7_4seq1.xml","form_type":"4"}},{"id":1620437,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-02-26T17:02:36.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":8252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on February 22, 2025."}],"balance_after":8252,"derivative":{"exercise_price":27.94,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":8252},"source":{"system":"sec-edgar","filing":"0001104659-24-027579","document":"tm247055-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465924027579/tm247055-7_4seq1.xml","form_type":"4"}},{"id":1735209,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-11-20T17:00:07.000Z","date":"2023-11-16","kind":"exercise","planned":false,"acquired":false,"shares":7457,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":9.24,"exercise_date":"2015-01-21","expiration_date":"2024-01-21","underlying":"Common Stock","underlying_shares":7457},"source":{"system":"sec-edgar","filing":"0001104659-23-119962","document":"tm2331055-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923119962/tm2331055-2_4seq1.xml","form_type":"4"}},{"id":1735208,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T17:00:07.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":2500,"price":28.01,"value":70025.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of common stock sold to cover the exercise price of the employee stock options."}],"balance_after":117089,"source":{"system":"sec-edgar","filing":"0001104659-23-119962","document":"tm2331055-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923119962/tm2331055-2_4seq1.xml","form_type":"4"}},{"id":1735207,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T17:00:07.000Z","date":"2023-11-16","kind":"exercise","planned":false,"acquired":true,"shares":7457,"price":9.24,"value":68902.68,"ownership":{"direct":true},"balance_after":119589,"source":{"system":"sec-edgar","filing":"0001104659-23-119962","document":"tm2331055-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923119962/tm2331055-2_4seq1.xml","form_type":"4"}},{"id":1991213,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-27T17:02:10.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":3886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024."}],"balance_after":3886,"derivative":{"underlying":"Common Stock","underlying_shares":3886},"source":{"system":"sec-edgar","filing":"0001104659-23-026081","document":"tm237737-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923026081/tm237737-15_4seq1.xml","form_type":"4"}},{"id":1991212,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-02-27T17:02:10.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":6293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on February 23, 2024."}],"balance_after":6293,"derivative":{"exercise_price":38.6,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":6293},"source":{"system":"sec-edgar","filing":"0001104659-23-026081","document":"tm237737-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923026081/tm237737-15_4seq1.xml","form_type":"4"}},{"id":1994211,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-24T17:08:11.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":3882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3882},"source":{"system":"sec-edgar","filing":"0001104659-23-025374","document":"tm237737-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923025374/tm237737-1_4seq1.xml","form_type":"4"}},{"id":1994210,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-24T17:08:11.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":3882,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":112132,"source":{"system":"sec-edgar","filing":"0001104659-23-025374","document":"tm237737-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923025374/tm237737-1_4seq1.xml","form_type":"4"}},{"id":2026951,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-08T17:00:58.000Z","date":"2018-04-17","kind":"gift","acquired":false,"shares":2203,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":108250,"source":{"system":"sec-edgar","filing":"0001104659-23-014592","document":"tm235112-4_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465923014592/tm235112-4_5seq1.xml","form_type":"5"}},{"id":2074552,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-12-30T17:01:49.000Z","date":"2022-12-28","kind":"exercise","acquired":false,"shares":8722,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":7.9,"exercise_date":"2014-02-05","expiration_date":"2023-02-05","underlying":"Common Stock","underlying_shares":8722},"source":{"system":"sec-edgar","filing":"0001104659-22-131398","document":"tm2233689-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465922131398/tm2233689-1_4seq1.xml","form_type":"4"}},{"id":2074551,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T17:01:49.000Z","date":"2022-12-28","kind":"exercise","acquired":true,"shares":8722,"price":7.9,"value":68903.8,"ownership":{"direct":true},"balance_after":110453,"source":{"system":"sec-edgar","filing":"0001104659-22-131398","document":"tm2233689-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465922131398/tm2233689-1_4seq1.xml","form_type":"4"}},{"id":2375949,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-24T21:23:29.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":3882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023."}],"balance_after":3882,"derivative":{"underlying":"Common Stock","underlying_shares":3882},"source":{"system":"sec-edgar","filing":"0001104659-22-026875","document":"tm227622-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465922026875/tm227622-2_4seq1.xml","form_type":"4"}},{"id":2375948,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-02-24T21:23:29.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":6847,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6847,"derivative":{"exercise_price":32.2,"exercise_date":"2023-02-22","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":6847},"source":{"system":"sec-edgar","filing":"0001104659-22-026875","document":"tm227622-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465922026875/tm227622-2_4seq1.xml","form_type":"4"}},{"id":2379847,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-23T16:20:38.000Z","date":"2022-02-19","kind":"disposition_to_issuer","acquired":false,"shares":4222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4222},"source":{"system":"sec-edgar","filing":"0001104659-22-026109","document":"tm227492-5_4seq.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465922026109/tm227492-5_4seq.xml","form_type":"4"}},{"id":2379846,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-23T16:20:38.000Z","date":"2022-02-19","kind":"grant","acquired":true,"shares":4222,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":101731,"source":{"system":"sec-edgar","filing":"0001104659-22-026109","document":"tm227492-5_4seq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465922026109/tm227492-5_4seq.xml","form_type":"4"}},{"id":2840651,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-02-23T18:46:56.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":4222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022."}],"balance_after":4222,"derivative":{"underlying":"Common Stock","underlying_shares":4222},"source":{"system":"sec-edgar","filing":"0001104659-21-026927","document":"tm217706-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465921026927/tm217706-2_4seq1.xml","form_type":"4"}},{"id":2840650,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-02-23T18:46:56.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":7365,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7365,"derivative":{"exercise_price":29.61,"exercise_date":"2022-02-19","expiration_date":"2031-02-19","underlying":"Common Stock","underlying_shares":7365},"source":{"system":"sec-edgar","filing":"0001104659-21-026927","document":"tm217706-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465921026927/tm217706-2_4seq1.xml","form_type":"4"}},{"id":3250313,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-02-25T17:59:15.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":9305,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9305,"derivative":{"exercise_price":23.99,"exercise_date":"2021-02-21","expiration_date":"2030-02-21","underlying":"Common Stock","underlying_shares":9305},"source":{"system":"sec-edgar","filing":"0001104659-20-024891","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465920024891/a4.xml","form_type":"4"}},{"id":3250312,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-25T17:59:15.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":5211,"price":23.99,"value":125011.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit component of the annual equity compensation to directors.  These shares will be settled in common stock upon vesting, such vesting to occur on February 21, 2021.  Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."}],"balance_after":97509,"source":{"system":"sec-edgar","filing":"0001104659-20-024891","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465920024891/a4.xml","form_type":"4"}},{"id":3633525,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-02-26T19:25:01.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":12427,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12427,"derivative":{"exercise_price":36.75,"exercise_date":"2020-02-22","expiration_date":"2029-02-22","underlying":"Common Stock","underlying_shares":12427},"source":{"system":"sec-edgar","filing":"0001104659-19-010795","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465919010795/a4.xml","form_type":"4"}},{"id":4031423,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-02-27T17:48:06.000Z","date":"2018-02-23","kind":"grant","acquired":true,"shares":8613,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8613,"derivative":{"exercise_price":39.4,"exercise_date":"2019-02-23","expiration_date":"2028-02-23","underlying":"Common Stock","underlying_shares":8613},"source":{"system":"sec-edgar","filing":"0001104659-18-012894","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465918012894/a4.xml","form_type":"4"}},{"id":4281384,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-06-15T16:42:06.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":6036,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6036,"derivative":{"exercise_price":38.6,"exercise_date":"2018-06-13","expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":6036},"source":{"system":"sec-edgar","filing":"0001104659-17-039592","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465917039592/a4.xml","form_type":"4"}},{"id":4422563,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":64775,"kind":"person","name":"NEWHALL CHARLES W III","position":1,"cik":"0001005544","reported_name":"NEWHALL CHARLES W III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-02-27T21:57:11.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":7905,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7905,"derivative":{"exercise_price":25.3,"exercise_date":"2018-02-24","expiration_date":"2027-02-24","underlying":"Common Stock","underlying_shares":7905},"source":{"system":"sec-edgar","filing":"0001104659-17-012173","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005544/000110465917012173/a4.xml","form_type":"4"}}]}